Targeting HIF2α therapy has gained considerable attention, and both PT2385117 and PT2977 (recently identified as “MK-6482”) have demonstrated targeted anti-tumor activity in mouse xenograft models of ccRCC as HIF2α inhibitors [79–81]. This evidence concerns the gene EPAS1 and neoplasm.